Active, not recruitingPHASE1, PHASE2NCT04910022
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nerviano Medical Sciences
- Intervention
- NMS-03305293(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (18)
- Mayo Clinic Hospital - Phoenix, Phoenix, Arizona, United States
- University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- University of Utah, University Hospital, Salt Lake City, Utah, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
- Swedish Medical Center - First Hill Campus, Seattle, Washington, United States
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
- Istituto Oncologico Veneto - IRCCS, Padua, Italy
- Istituto Clinico Humanitas, Rozzano, Italy
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04910022 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland